


Our key figures


Our revenue decreased by 0.6% (decrease 1.5% organically). We delivered profitability of 19.1% adjusted EBITDA margin and a free cash flow of CHF 39.6 million.

Share of revenue by business unit
2024



- 23.9% Dental
- 9.0% Drug Delivery
- 3.7% Surgery
- 26.2% Industry
- 37.3% Beauty

Share of revenue by business unit
2023



- 21.8% Dental
- 11.0% Drug Delivery
- 3.5% Surgery
- 26.9% Industry
- 36.7% Beauty

Key figures

millions of CHF	2024	% of revenue	+/-% change	2023	% of revenue
Revenue	483.9	100.0%	-0.6%	486.6	100.0%
Organic revenue growth ¹⁾			-1.5%		
Gross profit	159.7	33.0%	1.3%	157.6	32.4%
Operating income (EBIT)	12.9	2.7%	-19.0%	16.0	3.3%
EBITDA	74.5	15.4%	0.2%	74.4	15.3%
Adjusted EBITDA	92.5	19.1%	-0.7%	93.1	19.1%
Net income	-6.4	-1.3%	n/a	0.7	0.1%
Free cash flow (FCF)	39.6		n/a	3.4	
Operating net cash flow (ONCF)	61.0		239.8%	17.9	
Capital expenditure, net (capex, net)	44.3		-33.3%	66.3	
Net debt as of December 31	205.3		-6.3%	219.0	
Net debt adjusted EBITDA ratio as of December 31	2.22		-5.6%	2.35	
Employees (number of full-time equivalents) as of December 31	2'684		1.0%	2'658	

1) Adjusted for currency effects.

Stock market information

	2024	2023
Registered share (in CHF)		
– high	18.68	26.38
– low	8.28	16.45
– year-end	8.80	19.00
Market capitalization as of December 31		
– number of shares issued	41'262'370	41'262'370
– in millions of CHF	363.1	784.0
– in percentage of equity	83%	168%
P/E ratio as of December 31	-48.7x	2674.3x
Dividend yield as of December 31	5.7%	2.6%

Data per share

CHF	2024	2023
Net income attributable to a shareholder of medmix Ltd	-0.18	0.01
Equity attributable to a shareholder of medmix Ltd	10.60	11.30
Ordinary dividend	0.50 ¹⁾	0.50
Payout ratio	-277%	7'038%
Average number of shares outstanding as of December 31	40'779'842	40'868'426

1) Proposal to the Annual General Meeting.

Shareholder structure as of December 31, 2024

Number of shares	Number of shareholders	Shareholding
1–100	2'485	0.3%
101–1'000	3'585	3.6%
1'001–10'000	1'019	7.0%
10'001–100'000	102	6.7%
More than 100'000	20	53.0%
Total registered shareholders and shares (excluding treasury shares medmix Ltd)	7'211	70.6%

Shareholder structure as of December 31, 2023


Number of shares	Number of shareholders	Shareholding
1–100	2'883	0.4%
101–1'000	4'187	3.9%
1'001–10'000	783	5.1%
10'001–100'000	92	6.2%
More than 100'000	22	52.6%
Total registered shareholders and shares (excluding treasury shares medmix Ltd)	7'967	68.2%

Global reach, local presence



Sustainability strategy and impact

Our strategy, long-standing commitments and ambitious targets are reflected in a comprehensive and pragmatic framework:



At medmix, our long-term success depends on sustainable and profitable growth and a flourishing planet. As a company with a long tradition in the world of precision instruments, we want to continue to have a positive influence on our industry by reconciling economic, social and environmental aspects and promoting sustainable practices.

We recognize our responsibility, both within the company and in the various communities where we operate. Our goal is to further strengthen our sustainability efforts and promote competitiveness and innovation. We work to minimize adverse impacts and maximize benefits, future-proof our growth and invest in building capabilities within our organization to adapt to the changing regulatory landscape.

People

As an aspiring employer of choice, we enable an inclusive workforce, develop impactful development opportunities and support employee engagement through an open and empowering culture.

We work to support our communities and our employees, whose safety is a key priority. We promote a safe and healthy work environment and are committed to eliminating hazards, reducing occupational health and safety risks for everyone present at our sites.

Planet

At medmix, we recognize the importance of taking a science-based approach to the reduction of our greenhouse gases to meet the goals of the Paris Agreement in limiting global warming to 1.5°C above pre-industrial levels.

We have a responsibility to act in tackling climate change, reducing pollution and waste, and being a good water steward to ensure a sustainable future for our planet.

Profit

We recognize that our responsibilities are not limited to delivering strong financial results. We proactively direct our resources towards innovations that contribute to more sustainable solutions.

medmix is committed to preventing corruption and has a zero-tolerance policy towards corrupt practices.

Commitments and progress

Our efforts across the three pillars are supported by initiatives such as enhanced engagement with stakeholders and improved transparency in our sustainability reporting.

Our actions align with our strategic goals and enhance our preparedness for climate-related risks while positioning us to capitalize on emerging opportunities in the evolving market landscape.

In 2024, we completed our climate scenario analysis to determine the resilience of our company to climate change issues, along with a new double materiality assessment integrating an additional financial perspective. We reviewed the results and adjusted our measures and actions accordingly.

Our commitment to sustainability has been recognized with an "A" score for Climate Change and an "A-" for Water Security in our 2024 CDP disclosure. This prestigious recognition from CDP highlights our dedication to transparency and proactive efforts implementing best practices in combatting climate issues and improving water stewardship.

Below are a selection of the commitments addressing our material issues – our progress is on track:

People	Planet	Profit
<ul style="list-style-type: none"> • Any case of reasonable suspicion of child labor will be investigated and acted upon. • Continually improve the employee Lost Time Injury Frequency rate by eliminating hazards and mitigating risks. • Promote inclusion, with an initial focus on diversity. • Virtual learning and training opportunities will be offered to all employees. • Benchmark to living wages¹, ensuring any gaps from evolving standards of living are closed by 2030. 	<ul style="list-style-type: none"> • 30% reduction in Scope 1, 2 and partial 3 CO_{2e} emissions² by 2025. • 50% reduction in Scope 1, 2 and 3 CO_{2e} emissions by 2030. • Net zero CO_{2e} emissions by 2050. • 100% low-carbon electricity used by 2025. • Zero waste to landfill by 2025. 	<ul style="list-style-type: none"> • Increase sales of sustainable³ products, making 15 available during 2024. • CDP Climate Change “C” score by 2025. • medmix performance assessed through EcoVadis, with a commitment to continual improvement.

1) The wage level necessary to afford a decent standard of living for workers and their families, taking into account country circumstances and calculated for work performed during normal hours (International Labour Organization (ILO) definition).
 2) Scope 1, 2 and partial 3 (upstream categories 3 and 6).
 3) Minimum 30% reduction in CO_{2e} cradle-to-gate compared with standard product.

Leading brands

Our company is organized into two segments –Healthcare and Consumer & Industrial– and five business units:

All of our business units benefit from our diversified exposure to growing end markets that are supported by long-term mega trends, such as the growing middle class, an aging population and the trend towards increased urbanization, homecare and sustainability.

Helping people live healthier and more confident lives

Our Healthcare segment is divided into the Dental, Drug Delivery and Surgery business units. In the Dental business unit, our customers use our mixing and delivery devices for a broad range of applications, such as prosthetics, restorations, anesthetics and aesthetics. The Drug Delivery unit offers drug delivery devices that are used to inject fertility drugs and growth hormones and to treat niche diabetes indications, osteoporosis and rare diseases. In the Surgery business unit, our mixing and delivery devices are used to inject bone tissue and to apply hemostatic sealants for internal and external wound treatment during surgical procedures.



Innovative, high-precision delivery

In our Consumer & Industrial segment, we operate through the Industry and Beauty business units. In the Industry business unit, our dispensers, cartridges and mixers are used in the construction, transportation (automotive, railways and aerospace), electronics assembly, infrastructure and DIY industries. In the Beauty unit, our micro-brushes are used for the application of makeup treatments, such as lash & brow serum or spot correctors, as well as for the application of skincare treatments such as anti-aging treatments.

We have a strong legacy of setting industry standards through the continuous launch of innovative products in the business-to-business (B2B) markets in which we operate.

